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Abstract 
Background: Chryseobacterium indologenes is an uncommon organism that has been documented to cause a vari-
ety of invasive infections mostly in hospitalized patients with severe underlying diseases.
Case presentation: A three-month-old female infant born at term by caesarean section with meningomyelocele 
and congenital diaphragmatic hernia had two surgeries for the repair of meningomyelocele and diaphragmatic 
hernia on her 3rd and 14th day, respectively. On the 3rd month of her life, she deteriorated clinically with fever, leuko-
cytosis and increase of acute-phase reactants. Gas exchange condition became worse than it was before. Respiratory 
secretions, oxygen requirements and ventilator demand increased. Chest X-ray showed bilateral pulmonary infiltrates. 
Bacteriological blood, urine and cerebrospinal fluid culture test results were negative. C. indologenes was isolated 
from tracheobronchial secretion sample obtained by endotracheal aspiration. Although susceptible to ciprofloxacin 
(MIC:0.5 gr/L), levofloxacin and piperacillin–tazobactam, the isolate was resistant to meropenem, imipenem and colis-
tin. She was treated with ciprofloxacin successfully. Her fever resolved and gas exchange condition improved after 
72 h of the treatment. The antibiotic treatment was given for a course of 14 days.
Conclusion: Chryseobacterium indologenes may emerge as a potential pathogen in infants with the factors such as 
invasive equipment, having underlying diseases and prolonged hospitalization.
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Background
Chryseobacterium indologenes is a Gram-negative, aero-
bic, non-fermenting, non-motile, catalase-, oxidase-, 
and indole positive bacillus. It is widely distributed in 
environmental sources including water, soil and plants 
(Omar et  al. 2014). It is possible that physicians may 
encounter this pathogenic microorganism in hospital 
environment such as mechanical ventilator circuits. C. 
indologenes is a very rare pathogen in human that has 
been reported to cause infections mostly in hospitalized 
patient with immunocompromised conditions or infants. 
C. indologenes is inherently resistant to many antimicro-
bial agents including carbapenems (Omar et al. 2014).
In our case, C. indologenes was isolated from a tracheo-
bronchial secretion sample in a 3-month-old infant diag-
nosed with ventilator-associated pneumonia.
Case description
A three-month-old female infant born at term by cae-
sarean section was prenatally diagnosed with meningo-
myelocele and congenital diaphragmatic hernia and was 
transferred to the neonatal intensive care unit (NICU) 
for further management. Because of severe dyspnea, she 
was intubated and given mechanical ventilatory support. 
She had two surgeries for the repair of meningomyelocele 
and congenital diaphragmatic hernia on the 3rd and 14th 
days of life, respectively. VP shunt was inserted when 
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she was one month old because of hydrocephalus. The 
patient had a bacteremia caused by Stenotrophomonas 
maltophilia. The pathogen was susceptible to ceftazidime 
and ciprofloxacin and treated with ceftazidime. After the 
completion of treatment period, the patient remained 
antibiotic-free for 7  days. While she was monitored 
on mechanical ventilation on the 3rd  month of life, she 
clinically deteriorated with fever (38.5 °C). Gas exchange 
condition became worse than it was before. Respiratory 
secretions, oxygen requirements and ventilator demand 
increased. Her laboratory findings showed leukocytosis 
with increased number of neutrophils (WBC: 14,500/
mm3, neutrophils: 8600/mm3) and high levels of acute 
phase reactant (C-reactive protein: 19.2  mg/dl). Chest 
X-ray showed bilateral pulmonary infiltrates compatible 
with pneumonia. Blood, cerebrospinal fluid, urine and 
tracheobronchial secretion specimen obtained by sterile 
endotracheal aspiration were sent to microbiology labo-
ratory for bacterial culture. Increased leukocytes were 
observed on smear of tracheobronchial secretion sam-
ple. Previous infection history caused by Stenotropho-
monas maltophilia bacteremia was considered and 
empiric antibiotic therapy with vancomycin, ceftazidime 
and ciprofloxacin were started. Tracheobronchial secre-
tion obtained by sterile endotracheal aspiration yielded 
yellow-colored colonies after 24  h incubation on sheep 
blood agar (Fig.  1a). Similar yellow-pigmented colonies 
were also observed on Müller-Hinton Agar (Fig.  1b). C. 
indologenes was identified by conventional methods, 
VITEK 2 ID-AST (bioM´erieux, France) fully automa-
tized system and Matrix-Assisted Laser Desorption/Ioni-
zation time-of-flight, Mass Spectrometry(MALDI-TOF 
MS). Based on sequencing result of partial 16S rRNA 
gene, the isolate matched 99 % identities with the region 
from 852 to 860  bp of the 16S rRNA sequence of C. 
indologenes strain (GenBank sequence ID: LN681561.1). 
There was no other co-pathogen. Antimicrobial suscep-
tibility testing was performed by both determining the 
minimal inhibitory concentration (MIC) value using 
microdilution method and measuring the inhibition zone 
diameter onto Mueller–Hinton agar (Oxoid Ltd., Basing-
stoke, UK) medium aerobically at 35 ± 2 °C for 18–24 h 
using Kirby-Bauer’s disk diffusion method according 
to Clinical and Laboratory Standards Institute (CLSI) 
guidelines for non-fermenting microorganisms. Anti-
microbial susceptibility testing of the organism revealed 
resistance to aminoglycosides, ceftazidime, meropenem, 
imipenem, colistin and was susceptible to ciprofloxacin, 
levofloxacin, piperacillin–tazobactam and cefepime.
Her fever resolved and gas exchange condition 
improved after 72 h of treatment. The patient gave a good 
clinical response with the empiric treatment. For this 
reason, we did not want to change ciprofloxacin, and the 
treatment was continued with ciprofloxacin monotherapy. 
Blood, urine and cerebrospinal fluid culture test results 
were negative. Repeated endotracheal aspiration speci-
men culture was also negative after 72 h of antibiotherapy. 
The antibiotic treatment was given for a course of 14 days.
Discussion
Chryseobacterium genus is a group of Gram-negative, 
aerobic bacilli that belong to Flavobacteriaceae family. 
C. indologenes is the most common species and was first 
described by Vandamme et al. in 1994 (Vandamme et al. 
1994). However C. indologenes is not a part of the human 
microflora, it can be found in water supplies in the hos-
pital environment. Contamination of the medical devices 
containing water (intubation tubes, respirators, humidifi-
ers, etc.) in hospital settings may lead to severe infections 
in hospitalized patients. Both long-term colonization 
with C. indologenes of medical devices and invasive infec-
tions have been reported Hsueh et al. (1996). It is known 
that the production of biofilm and protease activity by C. 
indologenes is an important mechanism involved in its 
virulence although the exact mechanism of pathogenicity 
is not well determined Hsueh et al. (1996).
Chryseobacterium indologenes infections in children are 
very rare and usually associated with the presence of inva-
sive medical equipment as in our case. It has been reported 
to cause a variety of invasive infections such as ventila-
tor-associated pneumonia, bacteremia, catheter-related 
bloodstream infection, lumboperitoneal shunt infection, 
pyelonephritis, biliary tract infections, peritonitis, ocular 
infections, surgical site infection, wound infection, endo-
carditis, and keratitis (Hsueh et al. 1996; Deng et al. 2015; 
Bayraktar et  al. 2007; Douvoyiannis et  al. 2010; Al-Tatari 
et  al. 2007). Besides the use of invasive medical devices, 
other important risk factors for C. indologenes infection 
are use of broad-spectrum antibiotics, underlying diseases 
and primary or acquired immunosuppressive conditions. 
Infections caused by C. indologenes are associated with a 
high mortality rate (Nemli et al. 2015).
Fig. 1 Yellow colonies of Chryseobacterium indologenes on sheep 
blood agar (a) and Müller-Hinton agar (b)
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Chryseobacterium indologenes is a rare pathogen isolated 
from clinical specimens, and its antimicrobial susceptibility 
pattern is not well defined. The organism has a limited anti-
microbial sensitivity. The choice of an effective antibiotic 
for the empirical treatment is difficult. Chryseobacterium 
organisms produce class A -lactamase and class B carbape-
nem-hydrolyzing -lactamase molecules that cause intrinsic 
carbapenem and cephalosporin resistance. C. indologenes is 
usually resistant to aminoglycosides, other -lactams, chlo-
ramphenicol, linezolid, and glycopeptides and is usually 
susceptible to ciprofloxacin, levofloxacin, trimethoprim-
sulfamethoxazole (TMP–SMX), and piperacillin–tazobac-
tam (Nemli et  al. 2015; Lin et al. 2010). According to the 
results of the SENTRY Antimicrobial Surveillance Pro-
gram, the most active antimicrobials against C. indologenes 
are quinolones (≥95  % susceptibility) and trimethoprim–
sulfamethoxazole (95  % susceptibility), followed by piper-
acillin–tazobactam (90  % susceptibility). Ciprofloxacin, 
cefepime, ceftazidime, piperacillin, and rifampin showed 
reasonable activity (85 % susceptibility) (Kirby et al. 2004). 
Due to the limited data in the pediatric age group, a stand-
ard and effective treatment for C. indologenes infections 
is still not clear. Our case was ventilator-associated pneu-
monia caused by C. indologenes, which was successfully 
treated with ciprofloxacin monotherapy.
Chryseobacterium indologenes is a widespread bacte-
rium in the environment, in particular on the wet surfaces 
of hospitals and water systems. Although there is not any 
outbreak report in pediatric wards, a distillate water tank 
was shown to be the source of C. indologenes that caused 
a blood stream infection (Bayraktar et  al. 2007). The 
organism may spread because of limited education of the 
healthcare personnel and incomplete adherence to infec-
tion control measures. The physician should report this 
rare pathogen to infection control department. If neces-
sary, environmental cultures should be performed to iden-
tify the source. Healthcare personnel have to be careful 
and they should be educated about the implementation of 
infection control measures, especially hand hygiene com-
pliance. We reported this case to our hospital infection 
control committee. Environmental cultures such as the 
respiratory circuit, humidifier, etc. were not performed. 
Contact isolation precautions were applied to the patient, 
and healthcare workers were educated and reinforced 
about infection control measures. Outbreak did not occur.
Review of the literature about C. indologenes 
infections in pediatric age groups
We searched for information about C. indologenes infec-
tions in the MEDLINE (PubMed, Ovid) database and 
could able to suitable  24 pediatric cases. Patients were 
excluded if they were an adult (>18  years) case from 
this review. The most important characteristics of cases 
were presented in Table  1. Gender was reported for 23 
patients, 12 (52 %) of them were female, and 16 (66.6 %) 
patients were  ≤1  year of age. Most of the patients 
(n  =  21, 87.5  %) had underlying conditions and only 6 
(25  %) patients had no medical device. Five patients (1, 
18, 20, 21, 23rd patients in Table  1) had co-infections, 
including Escherichia coli, Morganella morganii, Acine-
tobacter baumannii, vancomycin resistant enterococcus, 
Stenotrophomonas maltophilia and Burkholderia cepa-
cia. The most commonly used antibiotics were ciproflox-
acin and TMP-SMX. Four patients died and the mortality 
rate was found 16.6 % in this series.
Conclusion
Chryseobacterium indologenes may emerge as a poten-
tial pathogen in infants with risk factors such as invasive 
medical equipment, underlying diseases, broad-spectrum 
antibiotics usage and prolonged hospitalization. Physi-
cians should consider this pathogen in the etiology of 
medical device-associated infections. C. indologenes may 
have resistance to empirically administered antimicrobial 
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Table 1 Characteristics of pediatric cases caused by Chryseobacterium indologenes
No Age/sex Underlying condi-
tion
Medical device Infection type Treatment Outcome Year/reference
1 1 year/M Burn Ventilator VAP Ciprofloxacin, cefoxitin, 
amikacin
Died 1996/Hsueh et al. (1996)
2 5 year/F Neuroblastoma CVC Bacteremia NR Survived 1996/Hsueh et al. (1996)
3 1 year/F Hepatoblastoma CVC Bacteremia NR Survived 1996/Hsueh et al. (1996)




Bacteremia Ceftriaxone Survived 2005/(Cascio et al. 2005)
5 5 month/M Down syndrome, dia-
phragmatic hernia, 
ASD
Ventilator Bacteremia Vancomycin, ofloxacin Died 2007/(Bayraktar et al. 2007)






TMP–SMX, Rifampin Survived 2007/(Al-Tatari et al. 2007)
7 33 day/F None None Bacteremia Cefepime Survived 2010/(Douvoyiannis et al. 
2010)
8 2 month/M Hydrocephaly External shunt Meningitis, sepsis Ampicillin–sulbactam, 
levofloxacin
Died 2011/(Ceylan et al. 2011)
9 36 week new-
born/NR
Prematurity Ventilator Bacteremia Cefoperazone–sulbac-
tam
Survived 2011/(Sudharani and Asiya 
Saxena 2011)
10 20 day/M Complex congenital 
heart disease
Ventilator VAP Piperacillin–tazobactam Survived 2011/(Calderón et al. 2011)
11 8 day/F None None Meningitis Cefepime Survived 2013/(Hendaus and Zahral-
din 2013)
12 3 year/F Acute myeloid leu-
kemia
CVC CRBSI Ciprofloxacin, mino-
cycline
Survived 2013/(Kodama et al. 2013)







Survived 2013/(Ozcan et al. 2013)





Meningitis TMP–SMX, ceftazidime Survived 2014/(Olbrich et al. 2014)
15 6 day/F SGA None Meningitis, sepsis Ciprofloxacin, TMP–SMX Survived 2014/(Eshwara et al. 2014)
16 3 month/F ASD CVC Bacteremia TMP–SMX Survived 2014/(Aydin et al. 2014)









Survived 2014/(Alford and Shelton 
2014)
18 3 month/M Metabolic disease CVC, ventilator CRBSI Ciprofloxacin, imi-
penem, colimycin, 
linezolid
Died 2016/(Aykac et al. 2016)
19 2 year/F Congenital hydro-
cephalus
External shunt Meningitis Ciprofloxacin, TMP–SMX Survived 2016/(Aykac et al. 2016)
20 8 year/M Cystic fibrosis, 
nephrotic syndrome
None Pneumonia Ceftriaxone Survived 2016/(Aykac et al. 2016)
21 8 month/M Ileus CVC Bacteremia Ciprofloxacin, merope-
nem, vancomycin
Survived 2016/(Aykac et al. 2016)
22 16 month/F ITP, immunosuppres-
sive therapy
None Bacteremia Ceftriaxone Survived 2016/(Aykac et al. 2016)
23 3 year/F Cerebral palsy CVC CRBSI Meropenem, amikacin Survived 2016/(Aykac et al. 2016)




Survived 2016/(Srinivasan et al. 2016)
25 3 month/F Meningomyelocele, 
congenital dia-
phragmatic hernia
Ventilator VAP Ciprofloxacin Survived Our case
M male, F female, NR not reported, TMP–SMX Trimethoprim–Sulfamethoxazole, VAP ventilator-associated pneumonia, CVC central venous catheter, CRBSI catheter-
related blood stream infection, SGA small for gestational age, ASD atrial septal defect, ITP immune thrombocytopenic purpura
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treatment for nosocomial infections and antimicrobial 
susceptibility test results are important to guide the anti-
biotic treatment.
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